MAP2K7 and breast cancer: Mirzoeva et al. studied the activity of two MEK inhibitors in several breast cancer cell lines and identified a transcription signature enriched for components of the ERK pathway, predictive of sensitivity, and a signature enriched for genes of the PI3K pathway, associated with resistance to MEK inhibitors [92].